Europe Supports Autoantibodies as Biomarkers for T1D
It was 2015—five years ago—that three organizations (BreakthroughT1D, the Endocrine Society and the American Diabetes Association) published a statement urging…
In-Home Test Kits Make Screening Convenient and Easy
TrialNet—an international Breakthrough T1D-supported network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams dedicated to finding cures for…
Strengthening Type 1 Diabetes Science by Building Careers
Sometimes, the funding that Breakthrough T1D can provide for researchers is exactly the invitation they need to get into the…
Universal Screening for Type 1 Diabetes: Its Time has Come?
Universal screening for type 1 diabetes (T1D) is a priority for Breakthrough T1D, but the cost versus benefits remain unclear.…
A Team in Boston Trying to Prevent Type 1 Diabetes
Breakthrough T1D is funding work on multiple ways to delay or prevent the onset of type 1 diabetes (T1D). This…
Can Two Viral Drugs Halt Type 1 Diabetes?
Scientists in Norway are seeking participants for a clinical trial to see if a course of anti-viral treatment may stop…
FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention…
ADA Scientific Sessions Recap—T1D Prevention Research: Jessica Dunne, Ph.D.
There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here…
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune…
Multiple Benefits of Screening For Beta Cell Autoimmunity in Children
Learn more about Breakthrough T1D’s prevention research and the benefits of early detection for type 1 diabetes (T1D).
